• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-GFAP

GFAP Polyclonal Antibody for IF

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

IF

Conjugaison

CoraLite®594 Fluorescent Dye

N° de cat : CL594-16825

Synonymes

FLJ45472, GFAP



Applications testées

Résultats positifs en IFtissu cérébral de rat, tissu cérébral de souris

Dilution recommandée

ApplicationDilution
Immunofluorescence (IF)IF : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

CL594-16825 cible GFAP dans les applications de IF et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène GFAP Protéine recombinante Ag10423
Nom complet glial fibrillary acidic protein
Masse moléculaire calculée 432 aa, 50 kDa
Poids moléculaire observé 45-50 kDa
Numéro d’acquisition GenBankBC013596
Symbole du gène GFAP
Identification du gène (NCBI) 2670
Conjugaison CoraLite®594 Fluorescent Dye
Excitation/Emission maxima wavelengths588 nm / 604 nm
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS avec glycérol à 50 %, Proclin300 à 0,05 % et BSA à 0,5 %, pH 7,3.
Conditions de stockageStocker à -20 °C. Éviter toute exposition à la lumière. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Function
GFAP (Glial fibrillary acidic protein) is a type III intermediate filament (IF) protein specific to the central nervous system (CNS). GFAP is one of the main components of the intermediate filament network in astrocytes and has been proposed as playing a role in cell migration, cell motility, maintaining mechanical strength, and in mitosis.
Tissue specificity
GFAP is expressed in central nervous system cells, predominantly in astrocytes. GFAP is commonly used as an astrocyte marker. However, GFAP is also present in peripheral glia and in non-CNS cells, including fibroblasts, chondrocytes, lymphocytes, and liver stellate cells (PMID: 21219963).
Involvement in disease
  • Mutations in GFAP lead to Alexander disease (OMIM: 203450), an autosomal dominant CNS disorder. The mutations present in affected individuals are thought to be gain-of-function.
  • Upregulation of GFAP is a hallmark of reactive astrocytes, in which GFAP is present in hypertrophic cellular processes. Reactive astrogliosis is present in many neurological disorders, such as stroke, various neurodegenerative diseases (including Alzheimer's and Parkinson's disease), and neurotrauma.
Isoforms
Astrocytes express 10 different isoforms of GFAP that differ in the rod and tail domains (PMID: 25726916), which means that they differ in molecular size. Isoform expression varies during the development and across different subtypes of astrocytes. Not all isoforms are upregulated in reactive astrocytes.
Post-translational modifications
Intermediate filament proteins are regulated by phosphorylation. Six phosphorylation sites have been identified in GFAP protein, at least some of which are reported to control filament assembly (PMID: 21219963).
Cellular localization
GFAP localizes to intermediate filaments and stains well in astrocyte cellular processes.

Protocole

Product Specific Protocols
IF protocol for CL594 GFAP antibody CL594-16825Download protocol
Standard Protocols
Click here to view our Standard Protocols